Literature DB >> 17016605

Different molecular pathways determining extrahepatic and intrahepatic recurrences of hepatocellular carcinoma.

Norio Iizuka1, Takao Tamesa, Kazuhiko Sakamoto, Takanobu Miyamoto, Yoshihiko Hamamoto, Masaaki Oka.   

Abstract

Recent genome-wide screens have identified genes associated with the metastatic potential of hepatocellular carcinoma (HCC); however, there is little overlap between the identified genes, and interpretations of the results remain controversial. These inconsistencies may be related to differences in the sample populations, use of distinct microarray platforms and algorithms, and the complicated modes of HCC recurrence. We investigated the gene expression profiles of extrahepatic recurrence (EHR) and early intrahepatic recurrence (IHR), which are two representative modes of recurrence of HCC attributable to metastasis. We used DNA microarray analysis and identified 46 signature genes for EHR in 35 HCCs in a supervised learning manner. The obtained gene expression profile was compared with that for early IHR that was determined previously in the same manner. The 46 signature genes for EHR included many cell adhesion-related genes (ITGA6, SPP1, DNMBP, CD44 and POSTN), which all showed higher expression in HCC with EHR than in HCC without EHR. The 46 signature genes for early IHR included 10 immune response-related genes, which all showed lower expression in HCC with early IHR than in HCC without early IHR. The signature genes for EHR included only two immune response-related genes (P=0.013). These results suggest that alteration of the cell adhesion system plays a central role in EHR and that reduction of the immune response is a specific step in early IHR. These results indicate that the metastatic processes in EHR and early IHR involve different molecular pathways.

Entities:  

Mesh:

Year:  2006        PMID: 17016605

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  Sulfatase 1 and sulfatase 2 in hepatocellular carcinoma: associated signaling pathways, tumor phenotypes, and survival.

Authors:  Ju Dong Yang; Zhifu Sun; Chunling Hu; Jinping Lai; Rebecca Dove; Ikuo Nakamura; Ju-Seog Lee; Snorri S Thorgeirsson; Koo Jeong Kang; In-Sun Chu; Lewis R Roberts
Journal:  Genes Chromosomes Cancer       Date:  2011-02       Impact factor: 5.006

Review 2.  Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets.

Authors:  Tamara Severi; Hannah van Malenstein; Chris Verslype; Jos F van Pelt
Journal:  Acta Pharmacol Sin       Date:  2010-10-18       Impact factor: 6.150

3.  Hepatocarcinogenesis in transgenic mice carrying hepatitis B virus pre-S/S gene with the sW172* mutation.

Authors:  M-W Lai; K-H Liang; W-R Lin; Y-H Huang; S-F Huang; T-C Chen; C-T Yeh
Journal:  Oncogenesis       Date:  2016-12-05       Impact factor: 7.485

4.  Hepatitis B virus X protein enhances liver cancer cell migration by regulating calmodulin-associated actin polymerization.

Authors:  Mi-Jee Kim; Jinchul Kim; Jin-Su Im; Inho Kang; Jeong Keun Ahn
Journal:  BMB Rep       Date:  2021-12       Impact factor: 4.778

5.  CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection.

Authors:  Chau-Ting Yeh; Chia-Jung Kuo; Ming-Wei Lai; Tse-Ching Chen; Chun-Yen Lin; Ta-Sen Yeh; Wei-Chen Lee
Journal:  BMC Cancer       Date:  2009-09-11       Impact factor: 4.430

6.  Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma.

Authors:  Y Tokuhisa; N Iizuka; I Sakaida; T Moribe; N Fujita; T Miura; S Tamatsukuri; H Ishitsuka; K Uchida; S Terai; K Sakamoto; T Tamesa; M Oka
Journal:  Br J Cancer       Date:  2007-10-16       Impact factor: 7.640

7.  HERC5 is a prognostic biomarker for post-liver transplant recurrent human hepatocellular carcinoma.

Authors:  Feng Xue; Brandon W Higgs; Jiaqi Huang; Chris Morehouse; Wei Zhu; Xin Yao; Philip Brohawn; Zhan Xiao; Yinong Sebastian; Zheng Liu; Yun Xia; Dong Shen; Mike Kuziora; Zhengwei Dong; Hulin Han; Yi Gu; Jianren Gu; Qiang Xia; Yihong Yao
Journal:  J Transl Med       Date:  2015-12-11       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.